Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ATYR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsaTyr Pharma reports Q1 2026 financial results in routine earnings disclosure
Filed May 15, 2026 · Period ending May 15, 2026 · ~1 min read
Key Changes
-
medium
Company issued press release announcing financial results for quarter ended March 31, 2026. Actual figures not included in 8-K filing itself, only referenced as attached exhibit.
Item 2.02 verify on EDGAR →
Summary
aTyr Pharma filed a routine 8-K on May 15, 2026 to announce its first quarter 2026 financial results. The filing follows standard practice for quarterly earnings disclosures, with the company issuing a press release that was attached as an exhibit. The 8-K itself does not contain the actual financial figures or performance metrics. For retail investors, this is a procedural filing with no immediate red flags.
The key information would be in the press release itself (Exhibit 99.1), which would detail revenue, expenses, cash position, and any updates on clinical programs or business developments. Investors should review the full press release to assess the company's financial health and progress on its therapeutic pipeline. Watch for any guidance updates or commentary on cash runway in the complete earnings materials.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
aTyr Pharma announced Q1 2026 financial results via press release on May 15, 2026.
Added in current filing · verify on EDGAR →
On May 15, 2026, aTyr Pharma, Inc. issued a press release announcing financial results for the quarter ended March 31, 2026.
The company disclosed its first quarter 2026 financial results through a press release. The 8-K itself does not contain the actual financial figures, only references the press release as Exhibit 99.1. This is a standard quarterly earnings announcement filing.
Event · Item 9.01 — Financial Statements and Exhibits
aTYR Pharma filed an 8-K attaching a press release dated May 15, 2026; no material event details disclosed in the filing body.
Added in current filing · verify on EDGAR →
99.1
Press Release, dated May 15, 2026
The company attached a press release dated May 15, 2026 as Exhibit 99.1. The 8-K body does not describe the content of the press release, so the nature of the disclosed event cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify